Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- NLS Pharmaceutics Ltd (NASDAQ: NLSP) has announced new study data which support the mechanism of action for mazindol, the active compound in the Company's lead product candidate to treat narcolepsy, Quilience.
- Narcolepsy is a chronic sleep disorder caused by a deficiency in orexin, a neuropeptide that regulates the sleep-wake cycle.
- The new data confirm mazindol's Orexin-2 receptor (OX2R) agonist activity.
- In the pre-clinical study conducted by the Department of Biomedical Sciences at the University of Lausanne and sponsored by NLS, mice genetically modified not to express OX2R (Knock-Out mice) and Wild-Type mice (normal mice) were investigated for psychostimulant effects when mazindol was administered.
- The study demonstrated that Knock Out mice were 70% less sensitive to mazindol than normal mice, confirming mazindol's potent activity as an OX2R agonist.
- Price Action: NLSP shares are up 0.58% at $3.39 on the last check Tuesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!